The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The potential value of ultra-low-dose radiation therapy for lymphoma treatment
Lena Specht, MD, University of Copenhagen, Copenhagen, Denmark, discusses the potential of ultra-low-dose radiation therapy for treating certain types of lymphomas, particularly follicular lymphoma (FL) and marginal zone lymphoma (MZL). Dr Specht mentions an ongoing study exploring this approach. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, lymphomas are very radiosensitive and some of them, the indolent ones that are most similar to normal lymphocytes, are really exquisitely radiosensitive and even low doses like just 2 gray or 4 gray will kill almost all the tumor cells. So the research into this has led to the use of this very, very low dose for selected types of lymphomas, in particular follicular lymphomas and marginal zone lymphomas, which are extremely radiosensitive...
Well, lymphomas are very radiosensitive and some of them, the indolent ones that are most similar to normal lymphocytes, are really exquisitely radiosensitive and even low doses like just 2 gray or 4 gray will kill almost all the tumor cells. So the research into this has led to the use of this very, very low dose for selected types of lymphomas, in particular follicular lymphomas and marginal zone lymphomas, which are extremely radiosensitive. And a strategy has now evolved that we are going to test in a prospective study in the International Lymphoma Radiation Oncology Group, where we give just 4 gray to lesions of either follicular lymphoma or marginal zone lymphoma and then wait and see the effect for two to three months and in 80% of the cases the lesion will disappear and the effect is satisfactory and no further treatment is needed. But if further treatment is needed it is of course very easy to give further treatment to, for instance, the standard dose of 24 gray because we’ve given such a low dose beforehand. So this is a very attractive way of treating these lymphomas. The patient only needs to come for one treatment and there are absolutely no side effects because the dose is so low. So something to exploit further in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
